A reduction of PSD95 has been observed in many pathological conditions of the brain, including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, fragile X syndrome (FXS), and intellectual disability [50,51,52,53,54,55,56]. This evidence concerns the gene DLG4 and early-onset autosomal dominant Alzheimer disease.